{"created":"2023-05-15T09:03:48.259548+00:00","id":8153,"links":{},"metadata":{"_buckets":{"deposit":"01f2bd50-ccaf-4a70-a77a-8ace4ef45755"},"_deposit":{"created_by":14,"id":"8153","owners":[14],"pid":{"revision_id":0,"type":"depid","value":"8153"},"status":"published"},"_oai":{"id":"oai:sapmed.repo.nii.ac.jp:00008153","sets":["1875:1892:1908"]},"author_link":["6717","6718","6719","6720","6721"],"item_2_alternative_title_18":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Newly Diagnosed Malignant Glioma"}]},"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2008-03-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"21","bibliographicPageStart":"15","bibliographicVolumeNumber":"18","bibliographic_titles":[{"bibliographic_title":"北海道脳神経疾患研究所医誌 = Journal of Hokkaido Brain Research Foundation"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Temozolomide is an alkylating agent that has demonstrated clinical antitumor activity and a relatively well-tolerated safety profile in patients with malignant gliomas. We report the antitumor efficacy and safety profile of radiotherapy plus temozolomide in patients with malignant glioma at newly diagnosed. Twelve patients with astrocytic tumors (glioblasotoma [GB] : 5, anaplastic oligoastrocytoma [AOA] : 6, anaplastic astrocytoma [AA] : 1) were treated. Patients with newly diagnosed malignant glioma received radiotherapy (fractionated focal irradiation daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 54 Gy to 60 Gy) plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle). Median age was 56.2 years, and 92 percent of patients had undergone debulking surgery. At a median follow-up of 8 months, the median progression-free survival (PFS) was 10 months. Progression-free survival (PFS) at 6 months was 55%. The median overall survival was 11.9 months. The objective response rate was 50% (33% complete response [CR], 17% partial response [PR]), with an additional 17% of patients with stable disease (SD). Concomitant treatment with radiotherapy plus temozolomide resulted in lymphocytopenia (Common Toxity Criteria : CTC < Grade 2) in 100% of patients. Pneumocystis carinii pneumonia prophylaxis was required until recovery of lymphocytopenia (CTC < Grade 1). The addition of temozolomide to radiotherapy for newly diagnosed malignant glioma resulted in a clinically meaningful with minimal additional toxicity.","subitem_description_type":"Abstract"}]},"item_2_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"中村記念病院"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1340-5764","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"佐藤, 憲市"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"伊東, 民雄"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"尾崎, 義丸"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"及川, 光照"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"中村, 博彦"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-07-21"}],"displaytype":"detail","filename":"n1340576418115.pdf","filesize":[{"value":"1.8 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"n1340576418115.pdf","url":"https://sapmed.repo.nii.ac.jp/record/8153/files/n1340576418115.pdf"},"version_id":"39e11cde-ec15-49a5-b24b-662dbddc4744"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"temozolomide","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"radiotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"malignant glioma","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"初発悪性神経膠腫に対する放射線療法併用によるTemozolomideの治療効果","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"初発悪性神経膠腫に対する放射線療法併用によるTemozolomideの治療効果","subitem_title_language":"ja"}]},"item_type_id":"2","owner":"14","path":["1908"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2009-03-24"},"publish_date":"2009-03-24","publish_status":"0","recid":"8153","relation_version_is_last":true,"title":["初発悪性神経膠腫に対する放射線療法併用によるTemozolomideの治療効果"],"weko_creator_id":"14","weko_shared_id":-1},"updated":"2023-12-13T03:15:25.035123+00:00"}